Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I randomized double-blind placebo-controlled single and multiple ascending dose study of REVN24 in healthy male volunteers
jRCT2071230074Phase 1Suspended
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REVN-24 (6 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability. Started Oct 2023; status: suspended.
02
Drugs
REVN-24
Beyond the preview
Go deeper on jRCT2071230074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230074.